Telaprevir-based therapy in patients coinfected with chronic hepatitis C virus infection and HIV: INSIGHT study.
Identifieur interne : 002470 ( PubMed/Curation ); précédent : 002469; suivant : 002471Telaprevir-based therapy in patients coinfected with chronic hepatitis C virus infection and HIV: INSIGHT study.
Auteurs : Maria Luisa Montes [Espagne] ; Mark Nelson [Royaume-Uni] ; Pierre-Marie Girard [France] ; Joe Sasadeusz [Australie] ; Andrzej Horban [Pologne] ; Beatriz Grinsztejn [Brésil] ; Natalia Zakharova [Russie] ; Antonio Rivero [Espagne] ; Jacques Durant [France] ; Enrique Ortega-Gonzalez [Espagne] ; Erkki Lathouwers [Belgique] ; Katrien Janssen [Belgique] ; Sivi Ouwerkerk-Mahadevan [Belgique] ; James Witek [Oman] ; Juan González-García [Espagne]Source :
- The Journal of antimicrobial chemotherapy [ 1460-2091 ] ; 2016.
Descripteurs français
- KwdFr :
- Adolescent, Adulte, Adulte d'âge moyen, Antiviraux (administration et posologie), Antiviraux (effets indésirables), Antiviraux (pharmacocinétique), Co-infection (traitement médicamenteux), Effets secondaires indésirables des médicaments (anatomopathologie), Effets secondaires indésirables des médicaments (épidémiologie), Femelle, Humains, Hépatite C chronique (), Hépatite C chronique (traitement médicamenteux), Infections à VIH (), Infections à VIH (traitement médicamenteux), Interféron alpha (administration et posologie), Interféron alpha (effets indésirables), Interféron alpha (pharmacocinétique), Jeune adulte, Mâle, Oligopeptides (administration et posologie), Oligopeptides (effets indésirables), Oligopeptides (pharmacocinétique), Polyéthylène glycols (administration et posologie), Polyéthylène glycols (effets indésirables), Polyéthylène glycols (pharmacocinétique), Protéines recombinantes (administration et posologie), Protéines recombinantes (effets indésirables), Protéines recombinantes (pharmacocinétique), Ribavirine (administration et posologie), Ribavirine (effets indésirables), Ribavirine (pharmacocinétique), Résultat thérapeutique, Sujet âgé.
- MESH :
- administration et posologie : Antiviraux, Interféron alpha, Oligopeptides, Polyéthylène glycols, Protéines recombinantes, Ribavirine.
- anatomopathologie : Effets secondaires indésirables des médicaments.
- effets indésirables : Antiviraux, Interféron alpha, Oligopeptides, Polyéthylène glycols, Protéines recombinantes, Ribavirine.
- pharmacocinétique : Antiviraux, Interféron alpha, Oligopeptides, Polyéthylène glycols, Protéines recombinantes, Ribavirine.
- traitement médicamenteux : Co-infection, Hépatite C chronique, Infections à VIH.
- épidémiologie : Effets secondaires indésirables des médicaments.
- Adolescent, Adulte, Adulte d'âge moyen, Femelle, Humains, Hépatite C chronique, Infections à VIH, Jeune adulte, Mâle, Résultat thérapeutique, Sujet âgé.
English descriptors
- KwdEn :
- Adolescent, Adult, Aged, Antiviral Agents (administration & dosage), Antiviral Agents (adverse effects), Antiviral Agents (pharmacokinetics), Coinfection (drug therapy), Drug-Related Side Effects and Adverse Reactions (epidemiology), Drug-Related Side Effects and Adverse Reactions (pathology), Female, HIV Infections (complications), HIV Infections (drug therapy), Hepatitis C, Chronic (complications), Hepatitis C, Chronic (drug therapy), Humans, Interferon-alpha (administration & dosage), Interferon-alpha (adverse effects), Interferon-alpha (pharmacokinetics), Male, Middle Aged, Oligopeptides (administration & dosage), Oligopeptides (adverse effects), Oligopeptides (pharmacokinetics), Polyethylene Glycols (administration & dosage), Polyethylene Glycols (adverse effects), Polyethylene Glycols (pharmacokinetics), Recombinant Proteins (administration & dosage), Recombinant Proteins (adverse effects), Recombinant Proteins (pharmacokinetics), Ribavirin (administration & dosage), Ribavirin (adverse effects), Ribavirin (pharmacokinetics), Treatment Outcome, Young Adult.
- MESH :
- chemical , administration & dosage : Antiviral Agents, Interferon-alpha, Oligopeptides, Polyethylene Glycols, Recombinant Proteins, Ribavirin.
- chemical , adverse effects : Antiviral Agents, Interferon-alpha, Oligopeptides, Polyethylene Glycols, Recombinant Proteins, Ribavirin.
- chemical , pharmacokinetics : Antiviral Agents, Interferon-alpha, Oligopeptides, Polyethylene Glycols, Recombinant Proteins, Ribavirin.
- complications : HIV Infections, Hepatitis C, Chronic.
- drug therapy : Coinfection, HIV Infections, Hepatitis C, Chronic.
- epidemiology : Drug-Related Side Effects and Adverse Reactions.
- pathology : Drug-Related Side Effects and Adverse Reactions.
- Adolescent, Adult, Aged, Female, Humans, Male, Middle Aged, Treatment Outcome, Young Adult.
Abstract
INSIGHT (ClinicalTrials.gov NCT01513941) evaluated the efficacy, safety and pharmacokinetics of telaprevir-based therapy and specific antiretroviral agents in hepatitis C virus genotype 1 (HCV-1)/HIV-1-coinfected patients.
DOI: 10.1093/jac/dkv323
PubMed: 26483516
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :002538
Links to Exploration step
pubmed:26483516Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Telaprevir-based therapy in patients coinfected with chronic hepatitis C virus infection and HIV: INSIGHT study.</title>
<author><name sortKey="Montes, Maria Luisa" sort="Montes, Maria Luisa" uniqKey="Montes M" first="Maria Luisa" last="Montes">Maria Luisa Montes</name>
<affiliation wicri:level="1"><nlm:affiliation>Servicio de Medicina Interna, Unidad de VIH, IdiPAZ, Hospital Universitario La Paz, Madrid, Spain.</nlm:affiliation>
<country xml:lang="fr">Espagne</country>
<wicri:regionArea>Servicio de Medicina Interna, Unidad de VIH, IdiPAZ, Hospital Universitario La Paz, Madrid</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Nelson, Mark" sort="Nelson, Mark" uniqKey="Nelson M" first="Mark" last="Nelson">Mark Nelson</name>
<affiliation wicri:level="1"><nlm:affiliation>Chelsea and Westminster Hospital, London, UK.</nlm:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Chelsea and Westminster Hospital, London</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Girard, Pierre Marie" sort="Girard, Pierre Marie" uniqKey="Girard P" first="Pierre-Marie" last="Girard">Pierre-Marie Girard</name>
<affiliation wicri:level="1"><nlm:affiliation>Hôpital St Antoine and INSERM, UMR S1136, Institut Pierre Louis d'Epidémiologie et de Santé Publique, Paris, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Hôpital St Antoine and INSERM, UMR S1136, Institut Pierre Louis d'Epidémiologie et de Santé Publique, Paris</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Sasadeusz, Joe" sort="Sasadeusz, Joe" uniqKey="Sasadeusz J" first="Joe" last="Sasadeusz">Joe Sasadeusz</name>
<affiliation wicri:level="1"><nlm:affiliation>Victorian Infectious Diseases Service, Royal Melbourne Hospital, Melbourne, Victoria, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>Victorian Infectious Diseases Service, Royal Melbourne Hospital, Melbourne, Victoria</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Horban, Andrzej" sort="Horban, Andrzej" uniqKey="Horban A" first="Andrzej" last="Horban">Andrzej Horban</name>
<affiliation wicri:level="1"><nlm:affiliation>Warsaw Medical University and Hospital of Infectious Diseases, Warsaw, Poland.</nlm:affiliation>
<country xml:lang="fr">Pologne</country>
<wicri:regionArea>Warsaw Medical University and Hospital of Infectious Diseases, Warsaw</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Grinsztejn, Beatriz" sort="Grinsztejn, Beatriz" uniqKey="Grinsztejn B" first="Beatriz" last="Grinsztejn">Beatriz Grinsztejn</name>
<affiliation wicri:level="1"><nlm:affiliation>STD/AIDS Clinical Research Laboratory, Instituto de Pesquisa Clínica Evandro Chagas, Rio de Janeiro, Brazil.</nlm:affiliation>
<country xml:lang="fr">Brésil</country>
<wicri:regionArea>STD/AIDS Clinical Research Laboratory, Instituto de Pesquisa Clínica Evandro Chagas, Rio de Janeiro</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Zakharova, Natalia" sort="Zakharova, Natalia" uniqKey="Zakharova N" first="Natalia" last="Zakharova">Natalia Zakharova</name>
<affiliation wicri:level="1"><nlm:affiliation>Saint-Petersburg AIDS Center, St Petersburg, Russian Federation.</nlm:affiliation>
<country xml:lang="fr">Russie</country>
<wicri:regionArea>Saint-Petersburg AIDS Center, St Petersburg</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Rivero, Antonio" sort="Rivero, Antonio" uniqKey="Rivero A" first="Antonio" last="Rivero">Antonio Rivero</name>
<affiliation wicri:level="1"><nlm:affiliation>Unidad de Enfermedades Infecciosas, Hospital Universitario Reina Sofía/IMIBIC, Córdoba, Spain.</nlm:affiliation>
<country xml:lang="fr">Espagne</country>
<wicri:regionArea>Unidad de Enfermedades Infecciosas, Hospital Universitario Reina Sofía/IMIBIC, Córdoba</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Durant, Jacques" sort="Durant, Jacques" uniqKey="Durant J" first="Jacques" last="Durant">Jacques Durant</name>
<affiliation wicri:level="1"><nlm:affiliation>Infectious Diseases Department, L'Archet Hospital, University of Nice, Nice, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Infectious Diseases Department, L'Archet Hospital, University of Nice, Nice</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Ortega Gonzalez, Enrique" sort="Ortega Gonzalez, Enrique" uniqKey="Ortega Gonzalez E" first="Enrique" last="Ortega-Gonzalez">Enrique Ortega-Gonzalez</name>
<affiliation wicri:level="1"><nlm:affiliation>Unidad de Enfermedades Infecciosas, Hospital General Universitario, Valencia, Spain.</nlm:affiliation>
<country xml:lang="fr">Espagne</country>
<wicri:regionArea>Unidad de Enfermedades Infecciosas, Hospital General Universitario, Valencia</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Lathouwers, Erkki" sort="Lathouwers, Erkki" uniqKey="Lathouwers E" first="Erkki" last="Lathouwers">Erkki Lathouwers</name>
<affiliation wicri:level="1"><nlm:affiliation>Janssen Infectious Diseases BVBA, Beerse, Belgium.</nlm:affiliation>
<country xml:lang="fr">Belgique</country>
<wicri:regionArea>Janssen Infectious Diseases BVBA, Beerse</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Janssen, Katrien" sort="Janssen, Katrien" uniqKey="Janssen K" first="Katrien" last="Janssen">Katrien Janssen</name>
<affiliation wicri:level="1"><nlm:affiliation>Janssen Infectious Diseases BVBA, Beerse, Belgium.</nlm:affiliation>
<country xml:lang="fr">Belgique</country>
<wicri:regionArea>Janssen Infectious Diseases BVBA, Beerse</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Ouwerkerk Mahadevan, Sivi" sort="Ouwerkerk Mahadevan, Sivi" uniqKey="Ouwerkerk Mahadevan S" first="Sivi" last="Ouwerkerk-Mahadevan">Sivi Ouwerkerk-Mahadevan</name>
<affiliation wicri:level="1"><nlm:affiliation>Janssen Infectious Diseases BVBA, Beerse, Belgium.</nlm:affiliation>
<country xml:lang="fr">Belgique</country>
<wicri:regionArea>Janssen Infectious Diseases BVBA, Beerse</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Witek, James" sort="Witek, James" uniqKey="Witek J" first="James" last="Witek">James Witek</name>
<affiliation wicri:level="1"><nlm:affiliation>Janssen Research & Development LLC, Titusville, NJ, USA jwitek@its.jnj.com.</nlm:affiliation>
<country wicri:rule="url">Oman</country>
<wicri:regionArea>Janssen Research & Development LLC, Titusville, NJ</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Gonzalez Garcia, Juan" sort="Gonzalez Garcia, Juan" uniqKey="Gonzalez Garcia J" first="Juan" last="González-García">Juan González-García</name>
<affiliation wicri:level="1"><nlm:affiliation>Servicio de Medicina Interna, Unidad de VIH, IdiPAZ, Hospital Universitario La Paz, Madrid, Spain.</nlm:affiliation>
<country xml:lang="fr">Espagne</country>
<wicri:regionArea>Servicio de Medicina Interna, Unidad de VIH, IdiPAZ, Hospital Universitario La Paz, Madrid</wicri:regionArea>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2016">2016</date>
<idno type="RBID">pubmed:26483516</idno>
<idno type="pmid">26483516</idno>
<idno type="doi">10.1093/jac/dkv323</idno>
<idno type="wicri:Area/PubMed/Corpus">002538</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">002538</idno>
<idno type="wicri:Area/PubMed/Curation">002470</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">002470</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Telaprevir-based therapy in patients coinfected with chronic hepatitis C virus infection and HIV: INSIGHT study.</title>
<author><name sortKey="Montes, Maria Luisa" sort="Montes, Maria Luisa" uniqKey="Montes M" first="Maria Luisa" last="Montes">Maria Luisa Montes</name>
<affiliation wicri:level="1"><nlm:affiliation>Servicio de Medicina Interna, Unidad de VIH, IdiPAZ, Hospital Universitario La Paz, Madrid, Spain.</nlm:affiliation>
<country xml:lang="fr">Espagne</country>
<wicri:regionArea>Servicio de Medicina Interna, Unidad de VIH, IdiPAZ, Hospital Universitario La Paz, Madrid</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Nelson, Mark" sort="Nelson, Mark" uniqKey="Nelson M" first="Mark" last="Nelson">Mark Nelson</name>
<affiliation wicri:level="1"><nlm:affiliation>Chelsea and Westminster Hospital, London, UK.</nlm:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Chelsea and Westminster Hospital, London</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Girard, Pierre Marie" sort="Girard, Pierre Marie" uniqKey="Girard P" first="Pierre-Marie" last="Girard">Pierre-Marie Girard</name>
<affiliation wicri:level="1"><nlm:affiliation>Hôpital St Antoine and INSERM, UMR S1136, Institut Pierre Louis d'Epidémiologie et de Santé Publique, Paris, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Hôpital St Antoine and INSERM, UMR S1136, Institut Pierre Louis d'Epidémiologie et de Santé Publique, Paris</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Sasadeusz, Joe" sort="Sasadeusz, Joe" uniqKey="Sasadeusz J" first="Joe" last="Sasadeusz">Joe Sasadeusz</name>
<affiliation wicri:level="1"><nlm:affiliation>Victorian Infectious Diseases Service, Royal Melbourne Hospital, Melbourne, Victoria, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>Victorian Infectious Diseases Service, Royal Melbourne Hospital, Melbourne, Victoria</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Horban, Andrzej" sort="Horban, Andrzej" uniqKey="Horban A" first="Andrzej" last="Horban">Andrzej Horban</name>
<affiliation wicri:level="1"><nlm:affiliation>Warsaw Medical University and Hospital of Infectious Diseases, Warsaw, Poland.</nlm:affiliation>
<country xml:lang="fr">Pologne</country>
<wicri:regionArea>Warsaw Medical University and Hospital of Infectious Diseases, Warsaw</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Grinsztejn, Beatriz" sort="Grinsztejn, Beatriz" uniqKey="Grinsztejn B" first="Beatriz" last="Grinsztejn">Beatriz Grinsztejn</name>
<affiliation wicri:level="1"><nlm:affiliation>STD/AIDS Clinical Research Laboratory, Instituto de Pesquisa Clínica Evandro Chagas, Rio de Janeiro, Brazil.</nlm:affiliation>
<country xml:lang="fr">Brésil</country>
<wicri:regionArea>STD/AIDS Clinical Research Laboratory, Instituto de Pesquisa Clínica Evandro Chagas, Rio de Janeiro</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Zakharova, Natalia" sort="Zakharova, Natalia" uniqKey="Zakharova N" first="Natalia" last="Zakharova">Natalia Zakharova</name>
<affiliation wicri:level="1"><nlm:affiliation>Saint-Petersburg AIDS Center, St Petersburg, Russian Federation.</nlm:affiliation>
<country xml:lang="fr">Russie</country>
<wicri:regionArea>Saint-Petersburg AIDS Center, St Petersburg</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Rivero, Antonio" sort="Rivero, Antonio" uniqKey="Rivero A" first="Antonio" last="Rivero">Antonio Rivero</name>
<affiliation wicri:level="1"><nlm:affiliation>Unidad de Enfermedades Infecciosas, Hospital Universitario Reina Sofía/IMIBIC, Córdoba, Spain.</nlm:affiliation>
<country xml:lang="fr">Espagne</country>
<wicri:regionArea>Unidad de Enfermedades Infecciosas, Hospital Universitario Reina Sofía/IMIBIC, Córdoba</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Durant, Jacques" sort="Durant, Jacques" uniqKey="Durant J" first="Jacques" last="Durant">Jacques Durant</name>
<affiliation wicri:level="1"><nlm:affiliation>Infectious Diseases Department, L'Archet Hospital, University of Nice, Nice, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Infectious Diseases Department, L'Archet Hospital, University of Nice, Nice</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Ortega Gonzalez, Enrique" sort="Ortega Gonzalez, Enrique" uniqKey="Ortega Gonzalez E" first="Enrique" last="Ortega-Gonzalez">Enrique Ortega-Gonzalez</name>
<affiliation wicri:level="1"><nlm:affiliation>Unidad de Enfermedades Infecciosas, Hospital General Universitario, Valencia, Spain.</nlm:affiliation>
<country xml:lang="fr">Espagne</country>
<wicri:regionArea>Unidad de Enfermedades Infecciosas, Hospital General Universitario, Valencia</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Lathouwers, Erkki" sort="Lathouwers, Erkki" uniqKey="Lathouwers E" first="Erkki" last="Lathouwers">Erkki Lathouwers</name>
<affiliation wicri:level="1"><nlm:affiliation>Janssen Infectious Diseases BVBA, Beerse, Belgium.</nlm:affiliation>
<country xml:lang="fr">Belgique</country>
<wicri:regionArea>Janssen Infectious Diseases BVBA, Beerse</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Janssen, Katrien" sort="Janssen, Katrien" uniqKey="Janssen K" first="Katrien" last="Janssen">Katrien Janssen</name>
<affiliation wicri:level="1"><nlm:affiliation>Janssen Infectious Diseases BVBA, Beerse, Belgium.</nlm:affiliation>
<country xml:lang="fr">Belgique</country>
<wicri:regionArea>Janssen Infectious Diseases BVBA, Beerse</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Ouwerkerk Mahadevan, Sivi" sort="Ouwerkerk Mahadevan, Sivi" uniqKey="Ouwerkerk Mahadevan S" first="Sivi" last="Ouwerkerk-Mahadevan">Sivi Ouwerkerk-Mahadevan</name>
<affiliation wicri:level="1"><nlm:affiliation>Janssen Infectious Diseases BVBA, Beerse, Belgium.</nlm:affiliation>
<country xml:lang="fr">Belgique</country>
<wicri:regionArea>Janssen Infectious Diseases BVBA, Beerse</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Witek, James" sort="Witek, James" uniqKey="Witek J" first="James" last="Witek">James Witek</name>
<affiliation wicri:level="1"><nlm:affiliation>Janssen Research & Development LLC, Titusville, NJ, USA jwitek@its.jnj.com.</nlm:affiliation>
<country wicri:rule="url">Oman</country>
<wicri:regionArea>Janssen Research & Development LLC, Titusville, NJ</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Gonzalez Garcia, Juan" sort="Gonzalez Garcia, Juan" uniqKey="Gonzalez Garcia J" first="Juan" last="González-García">Juan González-García</name>
<affiliation wicri:level="1"><nlm:affiliation>Servicio de Medicina Interna, Unidad de VIH, IdiPAZ, Hospital Universitario La Paz, Madrid, Spain.</nlm:affiliation>
<country xml:lang="fr">Espagne</country>
<wicri:regionArea>Servicio de Medicina Interna, Unidad de VIH, IdiPAZ, Hospital Universitario La Paz, Madrid</wicri:regionArea>
</affiliation>
</author>
</analytic>
<series><title level="j">The Journal of antimicrobial chemotherapy</title>
<idno type="eISSN">1460-2091</idno>
<imprint><date when="2016" type="published">2016</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adolescent</term>
<term>Adult</term>
<term>Aged</term>
<term>Antiviral Agents (administration & dosage)</term>
<term>Antiviral Agents (adverse effects)</term>
<term>Antiviral Agents (pharmacokinetics)</term>
<term>Coinfection (drug therapy)</term>
<term>Drug-Related Side Effects and Adverse Reactions (epidemiology)</term>
<term>Drug-Related Side Effects and Adverse Reactions (pathology)</term>
<term>Female</term>
<term>HIV Infections (complications)</term>
<term>HIV Infections (drug therapy)</term>
<term>Hepatitis C, Chronic (complications)</term>
<term>Hepatitis C, Chronic (drug therapy)</term>
<term>Humans</term>
<term>Interferon-alpha (administration & dosage)</term>
<term>Interferon-alpha (adverse effects)</term>
<term>Interferon-alpha (pharmacokinetics)</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Oligopeptides (administration & dosage)</term>
<term>Oligopeptides (adverse effects)</term>
<term>Oligopeptides (pharmacokinetics)</term>
<term>Polyethylene Glycols (administration & dosage)</term>
<term>Polyethylene Glycols (adverse effects)</term>
<term>Polyethylene Glycols (pharmacokinetics)</term>
<term>Recombinant Proteins (administration & dosage)</term>
<term>Recombinant Proteins (adverse effects)</term>
<term>Recombinant Proteins (pharmacokinetics)</term>
<term>Ribavirin (administration & dosage)</term>
<term>Ribavirin (adverse effects)</term>
<term>Ribavirin (pharmacokinetics)</term>
<term>Treatment Outcome</term>
<term>Young Adult</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Adolescent</term>
<term>Adulte</term>
<term>Adulte d'âge moyen</term>
<term>Antiviraux (administration et posologie)</term>
<term>Antiviraux (effets indésirables)</term>
<term>Antiviraux (pharmacocinétique)</term>
<term>Co-infection (traitement médicamenteux)</term>
<term>Effets secondaires indésirables des médicaments (anatomopathologie)</term>
<term>Effets secondaires indésirables des médicaments (épidémiologie)</term>
<term>Femelle</term>
<term>Humains</term>
<term>Hépatite C chronique ()</term>
<term>Hépatite C chronique (traitement médicamenteux)</term>
<term>Infections à VIH ()</term>
<term>Infections à VIH (traitement médicamenteux)</term>
<term>Interféron alpha (administration et posologie)</term>
<term>Interféron alpha (effets indésirables)</term>
<term>Interféron alpha (pharmacocinétique)</term>
<term>Jeune adulte</term>
<term>Mâle</term>
<term>Oligopeptides (administration et posologie)</term>
<term>Oligopeptides (effets indésirables)</term>
<term>Oligopeptides (pharmacocinétique)</term>
<term>Polyéthylène glycols (administration et posologie)</term>
<term>Polyéthylène glycols (effets indésirables)</term>
<term>Polyéthylène glycols (pharmacocinétique)</term>
<term>Protéines recombinantes (administration et posologie)</term>
<term>Protéines recombinantes (effets indésirables)</term>
<term>Protéines recombinantes (pharmacocinétique)</term>
<term>Ribavirine (administration et posologie)</term>
<term>Ribavirine (effets indésirables)</term>
<term>Ribavirine (pharmacocinétique)</term>
<term>Résultat thérapeutique</term>
<term>Sujet âgé</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Antiviral Agents</term>
<term>Interferon-alpha</term>
<term>Oligopeptides</term>
<term>Polyethylene Glycols</term>
<term>Recombinant Proteins</term>
<term>Ribavirin</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Antiviral Agents</term>
<term>Interferon-alpha</term>
<term>Oligopeptides</term>
<term>Polyethylene Glycols</term>
<term>Recombinant Proteins</term>
<term>Ribavirin</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="pharmacokinetics" xml:lang="en"><term>Antiviral Agents</term>
<term>Interferon-alpha</term>
<term>Oligopeptides</term>
<term>Polyethylene Glycols</term>
<term>Recombinant Proteins</term>
<term>Ribavirin</term>
</keywords>
<keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Antiviraux</term>
<term>Interféron alpha</term>
<term>Oligopeptides</term>
<term>Polyéthylène glycols</term>
<term>Protéines recombinantes</term>
<term>Ribavirine</term>
</keywords>
<keywords scheme="MESH" qualifier="anatomopathologie" xml:lang="fr"><term>Effets secondaires indésirables des médicaments</term>
</keywords>
<keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>HIV Infections</term>
<term>Hepatitis C, Chronic</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Coinfection</term>
<term>HIV Infections</term>
<term>Hepatitis C, Chronic</term>
</keywords>
<keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Antiviraux</term>
<term>Interféron alpha</term>
<term>Oligopeptides</term>
<term>Polyéthylène glycols</term>
<term>Protéines recombinantes</term>
<term>Ribavirine</term>
</keywords>
<keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Drug-Related Side Effects and Adverse Reactions</term>
</keywords>
<keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Drug-Related Side Effects and Adverse Reactions</term>
</keywords>
<keywords scheme="MESH" qualifier="pharmacocinétique" xml:lang="fr"><term>Antiviraux</term>
<term>Interféron alpha</term>
<term>Oligopeptides</term>
<term>Polyéthylène glycols</term>
<term>Protéines recombinantes</term>
<term>Ribavirine</term>
</keywords>
<keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Co-infection</term>
<term>Hépatite C chronique</term>
<term>Infections à VIH</term>
</keywords>
<keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr"><term>Effets secondaires indésirables des médicaments</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Adolescent</term>
<term>Adult</term>
<term>Aged</term>
<term>Female</term>
<term>Humans</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Treatment Outcome</term>
<term>Young Adult</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Adolescent</term>
<term>Adulte</term>
<term>Adulte d'âge moyen</term>
<term>Femelle</term>
<term>Humains</term>
<term>Hépatite C chronique</term>
<term>Infections à VIH</term>
<term>Jeune adulte</term>
<term>Mâle</term>
<term>Résultat thérapeutique</term>
<term>Sujet âgé</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">INSIGHT (ClinicalTrials.gov NCT01513941) evaluated the efficacy, safety and pharmacokinetics of telaprevir-based therapy and specific antiretroviral agents in hepatitis C virus genotype 1 (HCV-1)/HIV-1-coinfected patients.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">26483516</PMID>
<DateCreated><Year>2015</Year>
<Month>12</Month>
<Day>17</Day>
</DateCreated>
<DateCompleted><Year>2016</Year>
<Month>10</Month>
<Day>05</Day>
</DateCompleted>
<DateRevised><Year>2017</Year>
<Month>01</Month>
<Day>03</Day>
</DateRevised>
<Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1460-2091</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>71</Volume>
<Issue>1</Issue>
<PubDate><Year>2016</Year>
<Month>Jan</Month>
</PubDate>
</JournalIssue>
<Title>The Journal of antimicrobial chemotherapy</Title>
<ISOAbbreviation>J. Antimicrob. Chemother.</ISOAbbreviation>
</Journal>
<ArticleTitle>Telaprevir-based therapy in patients coinfected with chronic hepatitis C virus infection and HIV: INSIGHT study.</ArticleTitle>
<Pagination><MedlinePgn>244-50</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1093/jac/dkv323</ELocationID>
<Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">INSIGHT (ClinicalTrials.gov NCT01513941) evaluated the efficacy, safety and pharmacokinetics of telaprevir-based therapy and specific antiretroviral agents in hepatitis C virus genotype 1 (HCV-1)/HIV-1-coinfected patients.</AbstractText>
<AbstractText Label="PATIENTS AND METHODS" NlmCategory="METHODS">Open-label, Phase IIIb, multicentre study of telaprevir with pegylated-IFN (Peg-IFN) α2a and ribavirin in treatment-naive or -experienced HCV-1/HIV-1-coinfected patients on stable HIV HAART comprising efavirenz, atazanavir/ritonavir, darunavir/ritonavir, raltegravir, etravirine or rilpivirine with two nucleos(t)ide analogues. Patients received 750 mg telaprevir (1125 mg, if on efavirenz) every 8 h plus 180 μg/week Peg-IFNα2a and 800 mg/day ribavirin for 12 weeks, followed by Peg-IFNα2a and ribavirin alone for 12 weeks (HCV treatment naive and relapsers without cirrhosis, with extended rapid virological response) or 36 weeks (all others).</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">Overall, 162 patients (median age of 46 years, 78% male, 92% Caucasian and mean CD4 count of 687 cells/mm(3)) were treated; 13% had cirrhosis. One-hundred-and-thirty-two patients (81%) completed telaprevir; 14 (9%) discontinued due to an adverse event (AE). Sustained virological response (SVR) 12 rates (<25 IU/mL HCV RNA 12 weeks after the last planned treatment dose) in treatment-naive patients, relapsers and non-responders were 64% (41 of 64), 62% (18 of 29) and 49% (34 of 69), respectively. SVR12 rates ranged from 51% (33 of 65) (patients receiving efavirenz) to 77% (13 of 17) (patients receiving raltegravir). Most frequently reported AEs during telaprevir treatment were pruritus (43%) and rash (34%) special search categories. Anaemia special search category occurred in 15% of patients; 6% of patients reported a serious AE.</AbstractText>
<AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">In treatment-naive/-experienced HCV-1/HIV-1 patients there were significantly higher SVR rates with telaprevir-based therapy compared with pre-specified historical controls, and safety comparable to that in HCV-monoinfected patients.</AbstractText>
<CopyrightInformation>© The Author 2015. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Montes</LastName>
<ForeName>Maria Luisa</ForeName>
<Initials>ML</Initials>
<AffiliationInfo><Affiliation>Servicio de Medicina Interna, Unidad de VIH, IdiPAZ, Hospital Universitario La Paz, Madrid, Spain.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Nelson</LastName>
<ForeName>Mark</ForeName>
<Initials>M</Initials>
<AffiliationInfo><Affiliation>Chelsea and Westminster Hospital, London, UK.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Girard</LastName>
<ForeName>Pierre-Marie</ForeName>
<Initials>PM</Initials>
<AffiliationInfo><Affiliation>Hôpital St Antoine and INSERM, UMR S1136, Institut Pierre Louis d'Epidémiologie et de Santé Publique, Paris, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Sasadeusz</LastName>
<ForeName>Joe</ForeName>
<Initials>J</Initials>
<AffiliationInfo><Affiliation>Victorian Infectious Diseases Service, Royal Melbourne Hospital, Melbourne, Victoria, Australia.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Horban</LastName>
<ForeName>Andrzej</ForeName>
<Initials>A</Initials>
<AffiliationInfo><Affiliation>Warsaw Medical University and Hospital of Infectious Diseases, Warsaw, Poland.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Grinsztejn</LastName>
<ForeName>Beatriz</ForeName>
<Initials>B</Initials>
<AffiliationInfo><Affiliation>STD/AIDS Clinical Research Laboratory, Instituto de Pesquisa Clínica Evandro Chagas, Rio de Janeiro, Brazil.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Zakharova</LastName>
<ForeName>Natalia</ForeName>
<Initials>N</Initials>
<AffiliationInfo><Affiliation>Saint-Petersburg AIDS Center, St Petersburg, Russian Federation.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Rivero</LastName>
<ForeName>Antonio</ForeName>
<Initials>A</Initials>
<AffiliationInfo><Affiliation>Unidad de Enfermedades Infecciosas, Hospital Universitario Reina Sofía/IMIBIC, Córdoba, Spain.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Durant</LastName>
<ForeName>Jacques</ForeName>
<Initials>J</Initials>
<AffiliationInfo><Affiliation>Infectious Diseases Department, L'Archet Hospital, University of Nice, Nice, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Ortega-Gonzalez</LastName>
<ForeName>Enrique</ForeName>
<Initials>E</Initials>
<AffiliationInfo><Affiliation>Unidad de Enfermedades Infecciosas, Hospital General Universitario, Valencia, Spain.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Lathouwers</LastName>
<ForeName>Erkki</ForeName>
<Initials>E</Initials>
<AffiliationInfo><Affiliation>Janssen Infectious Diseases BVBA, Beerse, Belgium.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Janssen</LastName>
<ForeName>Katrien</ForeName>
<Initials>K</Initials>
<AffiliationInfo><Affiliation>Janssen Infectious Diseases BVBA, Beerse, Belgium.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Ouwerkerk-Mahadevan</LastName>
<ForeName>Sivi</ForeName>
<Initials>S</Initials>
<AffiliationInfo><Affiliation>Janssen Infectious Diseases BVBA, Beerse, Belgium.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Witek</LastName>
<ForeName>James</ForeName>
<Initials>J</Initials>
<AffiliationInfo><Affiliation>Janssen Research & Development LLC, Titusville, NJ, USA jwitek@its.jnj.com.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>González-García</LastName>
<ForeName>Juan</ForeName>
<Initials>J</Initials>
<AffiliationInfo><Affiliation>Servicio de Medicina Interna, Unidad de VIH, IdiPAZ, Hospital Universitario La Paz, Madrid, Spain.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName>
<AccessionNumberList><AccessionNumber>NCT01513941</AccessionNumber>
</AccessionNumberList>
</DataBank>
</DataBankList>
<PublicationTypeList><PublicationType UI="D017428">Clinical Trial, Phase III</PublicationType>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D016448">Multicenter Study</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2015</Year>
<Month>10</Month>
<Day>19</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>England</Country>
<MedlineTA>J Antimicrob Chemother</MedlineTA>
<NlmUniqueID>7513617</NlmUniqueID>
<ISSNLinking>0305-7453</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D016898">Interferon-alpha</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D009842">Oligopeptides</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D011994">Recombinant Proteins</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>30IQX730WE</RegistryNumber>
<NameOfSubstance UI="D011092">Polyethylene Glycols</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>49717AWG6K</RegistryNumber>
<NameOfSubstance UI="D012254">Ribavirin</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>655M5O3W0U</RegistryNumber>
<NameOfSubstance UI="C486464">telaprevir</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>Q46947FE7K</RegistryNumber>
<NameOfSubstance UI="C100416">peginterferon alfa-2a</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName>
<QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
<QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D060085" MajorTopicYN="N">Coinfection</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D064420" MajorTopicYN="N">Drug-Related Side Effects and Adverse Reactions</DescriptorName>
<QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
<QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D015658" MajorTopicYN="N">HIV Infections</DescriptorName>
<QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName>
<QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D019698" MajorTopicYN="N">Hepatitis C, Chronic</DescriptorName>
<QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName>
<QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D016898" MajorTopicYN="N">Interferon-alpha</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
<QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
<QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D009842" MajorTopicYN="N">Oligopeptides</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName>
<QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
<QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011092" MajorTopicYN="N">Polyethylene Glycols</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
<QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
<QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011994" MajorTopicYN="N">Recombinant Proteins</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
<QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
<QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D012254" MajorTopicYN="N">Ribavirin</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
<QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
<QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year>
<Month>03</Month>
<Day>17</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted"><Year>2015</Year>
<Month>09</Month>
<Day>08</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2015</Year>
<Month>10</Month>
<Day>21</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2015</Year>
<Month>10</Month>
<Day>21</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2016</Year>
<Month>10</Month>
<Day>7</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">26483516</ArticleId>
<ArticleId IdType="pii">dkv323</ArticleId>
<ArticleId IdType="doi">10.1093/jac/dkv323</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002470 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 002470 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Asie |area= AustralieFrV1 |flux= PubMed |étape= Curation |type= RBID |clé= pubmed:26483516 |texte= Telaprevir-based therapy in patients coinfected with chronic hepatitis C virus infection and HIV: INSIGHT study. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i -Sk "pubmed:26483516" \ | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd \ | NlmPubMed2Wicri -a AustralieFrV1
This area was generated with Dilib version V0.6.33. |